1. Dalen JE, Alpert JS, Goldberg RJ, Weinstein RS. The epidemic of the 20(th) century: coronary heart disease. Am J Med 2014;127:807-2.

2. Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol 2014;11:276-89.

3. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 2018;137:e67-492.

4. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al. Body mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373:1083-96.

5. Phillips CM. Metabolically healthy obesity: personalised and public health implications. Trends Endocrinol Metabol 2016;27:189-91.

6. Bradshaw PT, Monda KL, Stevens J. Metabolic syndrome in healthy obese, overweight, and normal weight individuals: the Atherosclerosis Risk in Communities Study. Obesity (Silver Spring) 2013;21:203-9.

7. Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol Sci 2015;36:461-70.

8. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.

9. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci 2013;9:191-200.

10. Gao X, Salomon C, Freeman DJ. Extracellular vesicles from adipose tissue - a potential role in obesity and type 2 diabetes? Front Endocrinol (Lausanne) 2017;8:202.

11. Vieira-Potter VJ. Inflammation and macrophage modulation in adipose tissues. Cell Microbiol 2014;16:1484-92.

12. Pellegrinelli V, Carobbio S, Vidal-Puig A. Adipose tissue plasticity: how fat depots respond differently to pathophysiological cues. Diabetologia 2016;59:1075-88.

13. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508-19.

14. Mathieu P, Poirier P, Pibarot, Lemieux I, Despres JP. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009;53:577-84.

15. Bobryshev YV. Monocyte recruitment and foam cell formation in atherosclerosis. Micron 2006;37:208-22.

16. Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res 2016;118:620-36.

17. Bhatt A, Rohatgi A. HDL cholesterol efflux capacity: cardiovascular risk factor and potential therapeutic target. Curr Atheroscler Rep 2016;18:2.

18. Maguire EM, Pearce SWA, Xiao Q. Foam cell formation: a new target for fighting atherosclerosis and cardiovascular disease. Vascul Pharmacol 2019;112:54-71.

19. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol 2011;31:1506-16.

20. Feig JE, Vengrenyuk Y, Reiser V, Wu C, Statnikov A, et al. Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome. PLoS One 2012;7:e39790.

21. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 2013;13:709-21.

22. Reiss AB, Anwar K, Merrill JT, Chan ES, Awadallah NW, et al. Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular disease. Rheumatol Int 2010;30:591-8.

23. Reiss AB, Wan DW, Anwar K, Merrill JT, Wirkowski PA, et al. Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis. Exp Biol Med (Maywood) 2009;234:354-60.

24. Reiss AB, Awadallah N, Malhotra S, Montesinos MC, Chan ESL, et al. Immune complexes and interferon-γ decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages. J Lipid Res 2001;42:1913-22.

25. Reiss AB, Patel CA, Rahman MM, Chan ES, Hasneen K, et al. IFN-gamma impedes reverse cholesterol transport and promotes foam cell transformation in THP-1 human monocytes/macrophages. Med Sci Monit 2004;10:BR420-5.

26. Reiss AB. Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus. Curr Rheumatol Rep 2009;11:255-60.

27. Voloshyna I, Modayil S, Littlefield MJ, Belilos E, Belostocki KB, et al. Plasma from rheumatoid arthritis patients promotes pro-atherogenic cholesterol transport gene expression in THP-1 human macrophages. Exp Biol Med (Maywood) 2013;238:1192-7.

28. Tan L, Liu L, Jiang Z, Hao X. Inhibition of microRNA-17-5p reduces the inflammation and lipid accumulation, and up-regulates ATP-binding cassette transporterA1 in atherosclerosis. J Pharmacol Sci 2019;139:280-8.

29. Choromańska B, Myśliwiec P, Choromańska K, Dadan J, Chabowski A. The role of CD36 receptor in the pathogenesis of atherosclerosis. Adv Clin Exp Med 2017;26:717-22.

30. Reardon CA, Lingaraju A, Schoenfelt KQ, Zhou G, Cui C, et al. Obesity and insulin resistance promote atherosclerosis through an IFNγ-regulated macrophage protein network. Cell Rep 2018;23:3021-30.

31. Zhu Y, Xian X, Wang Z, Bi Y, Chen Q, et al. Research progress on the relationship between atherosclerosis and inflammation. Biomolecules 2018;8:80.

32. Zhang L, Peppel K, Sivashanmugam P, Orman ES, Brian L, et al. Expression of tumor necrosis factor receptor-1 in arterial wall cells promotes atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:1087-94.

33. Howe KL, Fish JE. Transforming endothelial cells in atherosclerosis. Nat Metab 2019;1:856-7.

34. Yu XH, Zhang J, Zheng XL, Yang YH, Tang CK. Interferon-γ in foam cell formation and progression of atherosclerosis. Clin Chim Acta 2015;441:33-43.

35. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-7.

36. Hu D, Hannah J, Gray RS, Jablonski KA, Henderson JA, et al. Effects of obesity and body fat distribution on lipids and lipoproteins in nondiabetic american indians: the strong heart study. Obes Res 2000;8:411-21.

37. Franssen R, Monajemi H, Stroes ES, Kastelein JJ. Obesity and dyslipidemia. Med Clin North Am 2011;95:893-902.

38. Jellinger PS, Mehta AE, Smith DA, Handelsman Y, Ganda O, et al; AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. American Association of Clinical Endocrinologists’ Guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract 2012;18:1-78.

39. Rashid S, Genest J. Effect of obesity on high-density lipoprotein metabolism. Obesity 2007;15:2875-88.

40. Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013;5:1218-40.

41. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-600.

42. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102:1K-34K.

43. Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J 2005;81:358-66.

44. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J 2011;5:24-34.

45. Ottaviani E, Malagoli D, Franceschi C. The evolution of the adipose tissue: a neglected enigma. Gen Comp Endocrinol 2011;174:1-4.

46. Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012;126:1301-13.

47. Van Dam AD, Boon MR, Berbee JFP, Rensen PCN, Van Harmelen V. Targeting white, brown and perivascular adipose tissue in atherosclerosis development. Eur J Pharmacol 2017;816:82-92.

48. Frühbeck G, Gómez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001;280:E827-47.

49. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97.

50. Liberale L, Bonaventura A, Vecchiè A, Casula M, Dallegri F, et al. The role of adipocytokines in coronary atherosclerosis. Curr Atheroscler Rep 2017;19:10.

51. Blüher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 2009;117:241-50.

52. Ohman MK, Shen Y, Obimba CI, Wright AP, Warnock M, et al. Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008;117:798-805.

53. Pollack RM, Donath MY, LeRoith D, Leibowitz G. Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care 2016;39:S244-52.

54. O’Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 2014;312:1006-15.

55. Reiss AB, Vernice NA, Siegart NM, De Leon J, Kasselman LJ. Exosomes in cholesterol metabolism and atherosclerosis. Cardiovasc Hematol Disord Drug Targets 2017;17:185-94.

56. Hoeke G, Kooijman S, Boon MR, Rensen PCN, Berbée JF. Role of Brown fat in lipoprotein metabolism and atherosclerosis. Circ Res 2016;118:173-82.

57. Xiong W, Zhao X, Villacorta L, Rom O, Garciabarrio MT, et al. Brown adipocyte-specific PPARγ (peroxisome proliferator-activated receptor γ) deletion impairs perivascular adipose tissue development and enhances atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2018;38:1738-47.

58. Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab 2007;293:E444-52.

59. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009;360:1509-17.

60. Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, et al. Brown adipose tissue activity controls triglyceride clearance. Nat Med 2011;17:200-5.

61. Liu X, Zheng Z, Zhu X, Meng M, Li L, et al. Brown adipose tissue transplantation improves whole-body energy metabolism. Cell Res 2013;23:851-4.

62. Geerling JJ, Boon MR, van der Zon GC, van den Berg SA, van den Hoek AM, et al. Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice. Diabetes 2014;63:880-91.

63. Tanyanskiy DA, Pigarevskii PV, Maltseva SV, Denisenko AD. Immunohistochemical analysis of adiponectin in atherosclerotic lesions of human aorta. ARYA Atheroscler 2019;15:179-84.

64. Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci 2017;18:1321.

65. Magni P, Liuzzi A, Ruscica M, Dozio E, Ferrario S, et al. Free and bound plasma leptin in normal weight and obese men and women: relationship with body composition, resting energy expenditure, insulin-sensitivity, lipid profile and macronutrient preference. Clin Endocrinol (Oxf) 2005;62:189-96.

66. Hartwig S, De Filippo E, Göddeke S, Knebel B, Kotzka J, et al. Exosomal proteins constitute an essential part of the human adipose tissue secretome. Biochim Biophys Acta Proteins Proteom 2019;1867:140172.

67. Phoonsawat W, Aoki-Yoshida A, Tsuruta T, Sonoyama K. Adiponectin is partially associated with exosomes in mouse serum. Biochem Biophys Res Commun 2014;448:261-6.

68. Lee JE, Moon PG, Lee IK, Baek MC. Proteomic analysis of extracellular vesicles released by adipocytes of otsuka long-evans tokushima fatty (OLETF) rats. Protein J 2015;34:220-35.

69. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013;200:373-83.

70. Shah R, Patel T, Freedman JE. Circulating extracellular vesicles in human disease. N Engl J Med 2018;379:2180-1.

71. Haraszti RA, Didiot MC, Sapp E, Leszyk J, Shaffer SA, et al. High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J Extracell Vesicles 2016;5:32570.

72. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008;319:1244-7.

73. Skotland T, Hessvik NP, Sandvig K, Llorente A. Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology. J Lipid Res 2019;60:9-18.

74. Yoon Y, Kim O, Gho Y. Extracellular vesicles as emerging intercellular communicasomes. BMB Rep 2014;47:531-9.

75. O’Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol 2018;9:402.

76. Dini L, Tacconi S, Carata E, Tata AM, Vergallo C, et al. Microvesicles and exosomes in metabolic diseases and inflammation. Cytokine Growth Factor Rev 2020;51:27-39.

77. Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 2014;30:255-89.

78. Chen Y, Buyel JJ, Hanssen MJ, Siegel F, Pan R, et al. Exosomal microRNA miR-92a concentration in serum reflects human brown fat activity. Nat Commun ;7:11420.

79. Thomou T, Mori MA, Dreyfuss JM, Konishi M, Sakaguchi M, et al. Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature 2017;542:450-5.

80. Ortega FJ, Moreno M, Mercader JM, Moreno-Navarrete JM, Fuentes-Batllevell N, et al. Inflammation triggers specific microRNA profiles in human adipocytes and macrophages and in their supernatants. Clin Epigenetics 2015;7:49.

81. Ortega FJ, Mercader JM, Moreno-Navarrete JM, Nonell L, Puigdecanet E, et al. Surgery-induced weight loss is associated with the downregulation of genes targeted by microRNAs in adipose tissue. J Clin Endocrinol Metab 2015;100:E1467-76.

82. Ferrante SC, Nadler EP, Pillai DK, Hubal MJ, Wang Z, et al. Adipocyte-derived exosomal miRNAs: a novel mechanism for obesity-related disease. Pediatr Res 2015;77:447-54.

83. Chartoumpekis DV, Zaravinos A, Ziros PG, Iskrenova RP, Psyrogiannis AI, et al. Differential expression of microRNAs in adipose tissue after long-term high-fat diet-induced obesity in mice. PLoS One 2012;7:e34872.

84. Chang W, Wang J. Exosomes and their noncoding RNA cargo are emerging as new modulators for diabetes mellitus. Cells 2019;8:E853.

85. Mori MA, Thomou T, Boucher J, Lee KY, Lallukka S, et al. Altered miRNA processing disrupts brown/white adipocyte determination and associates with lipodystrophy. J Clin Invest 2014;124:3339-51.

86. Ying W, Riopel M, Bandyopadhyay G, Dong Y, Birmingham A, et al. Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. Cell 2017;171:372-84.e12.

87. Chen Y, Pfeifer A. Brown fat-derived exosomes: small vesicles with big impact. Cell Metab 2017;25:759-60.

88. Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev 2012;26:271-81.

89. Kokkinos J, Tang S, Rye KA, Ong KL. The role of fibroblast growth factor 21 in atherosclerosis. Atherosclerosis 2017;257:259-65.

90. Deng ZB, Poliakov A, Hardy RW, Clements R, Liu C, et al. Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance. Diabetes 2009;58:2498-505.

91. Curtiss LK, Tobias PS. Emerging role of toll-like receptors in atherosclerosis. J Lipid Res 2009;50:S340-5.

92. Xie Z, Wang X, Liu X, Du H, Sun C, et al. Adipose-derived exosomes exert proatherogenic effects by regulating macrophage foam cell formation and polarization. J Am Heart Assoc 2018;7:e007442.

93. Voloshyna I, Reiss AB. The ABC transporters in lipid flux and atherosclerosis. Prog Lipid Res 2011;50:213-24.

94. Barberio MD, Kasselman LJ, Playford MP, Epstein SB, Renna HA, et al. Cholesterol efflux alterations in adolescent obesity: role of adipose-derived extracellular vesical microRNAs. J Transl Med 2019;17:232.

95. Crewe C, Joffin N, Rutkowski JM, Kim M, Zhang F, et al. An endothelial-to-adipocyte extracellular vesicle axis governed by metabolic state. Cell 2018;175:695-708.

96. Zhao Q, Yang J, Liu B, Huang F, Li Y. Exosomes derived from mangiferin-stimulated perivascular adipose tissue ameliorate endothelial dysfunction. Mol Med Rep 2019;19:4797-805.

97. Kita S, Maeda N, Shimomura I. Interorgan communication by exosomes, adipose tissue, and adiponectin in metabolic syndrome. J Clin Invest 2019;129:4041-9.

98. Summerhill V, Orekhov A. Pericytes in atherosclerosis. Adv Exp Med Biol 2019;1147:279-97.

99. Orekhov AN, Bobryshev YV, Chistiakov DA. The complexity of cell composition of the intima of large arteries: focus on pericyte-like cells. Cardiovasc Res 2014;103:438-51.

100. Liu C, Ge HM, Liu BH, Dong R, Shan K, et al. Targeting pericyte-endothelial cell crosstalk by circular RNA-cPWWP2A inhibition aggravates diabetes-induced microvascular dysfunction. Proc Natl Acad Sci U S A 2019;116:7455-64.

101. Pan Y, Hui X, Hoo RLC, Ye D, Chan CYC, et al. Adipocyte-secreted exosomal microRNA-34a inhibits M2 macrophage polarization to promote obesity-induced adipose inflammation. J Clin Invest 2019;129:834-49.

102. Ogawa R, Tanaka C, Sato M, Nagasaki H, Sugimura K, et al. Adipocyte-derived microvesicles contain RNA that is transported into macrophages and might be secreted into blood circulation. Biochem Biophys Res Commun 2010;398:723-9.

103. Eguchi A, Lazic M, Armando AM, Phillips SA, Katebian R, et al. Circulating adipocyte-derived extracellular vesicles are novel markers of metabolic stress. J Mol Med (Berl) 2016;94:1241-53.

104. Kobayashi Y, Eguchi A, Tempaku M, Honda T, Togashi K, et al. Circulating extracellular vesicles are associated with lipid and insulin metabolism. Am J Physiol Endocrinol Metab 2018;315:E574-82.

105. Hubal MJ, Nadler EP, Ferrante SC, Barberio MD, Suh JH, et al. Circulating adipocyte-derived exosomal MicroRNAs associated with decreased insulin resistance after gastric bypass. Obesity (Silver Spring) 2017;25:102-10.

106. Zhao H, Shang Q, Pan Z, Bai Y, Li Z, et al. Exosomes from adipose-derived stem cells attenuate adipose inflammation and obesity through polarizing M2 macrophages and beiging in white adipose tissue. Diabetes 2018;67:235-47.

107. Chistiakov DA, Kashirskikh DA, Khotina VA, Grechko AV, Orekhov AN. Immune-inflammatory responses in atherosclerosis: the role of myeloid cells. J Clin Med 2019;8:1798.

108. Lu Z, Wang F, Yu P, Wang X, Wang Y, et al. Inhibition of miR-29b suppresses MAPK signaling pathway through targeting SPRY1 in atherosclerosis. Vascul Pharmacol 2018;102:29-36.

Vessel Plus
ISSN 2574-1209 (Online)
Follow Us


All published articles are preserved here permanently:


All published articles are preserved here permanently: